Hugh Smyth

Hugh Smyth has a diverse work experience spanning various roles and companies. Hugh co-founded Cloxero Therapeutics in 2019 and is currently serving as a Co-Founder. Prior to this, Hugh was a Professor at The University of Texas at Austin from 2009 to the present. Hugh held positions as a Professor, Associate Professor with Tenure, and Assistant Professor during their time at the university. Hugh also served as the Chief Technology Officer at Nob Hill Therapeutics starting in 2016. Hugh co-founded Via Therapeutics in 2014 and was a Co-Founder of the company. Hugh worked as the Editor in Chief of Drug Development and Industrial Pharmacy from 2014 to 2022. Hugh held the position of Chief Scientist at Respira Therapeutics from 2011 to 2021. Before joining The University of Texas, Hugh was an Assistant Professor at the University of New Mexico from 2005 to 2009 and a Research Assistant Professor at the University of North Carolina at Chapel Hill from 2003 to 2005. Hugh began their career as a Graduate Student at the University of Otago in 1997 and worked as a Research Associate at GlaxoWellcome from 1998 to 2000.

Hugh Smyth completed their education history as follows:

From 2001 to 2003, Hugh Smyth attended the University of North Carolina at Chapel Hill, where they pursued a postdoctoral degree in Drug Delivery.

From 1997 to 2000, they studied at the University of Otago, earning a Ph.D. in Drug Delivery.

Between 1987 and 1991, Hugh Smyth attended Mt Maunganui College, but it is unclear whether they obtained a degree or pursued a specific field of study during this period.